Half-year report · Q2

Period2024-01-01 → 2024-06-30
Filed2024-08-08
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
MetricValuePeriodScopeSource row
Revenue¥316m2024-01-01 → 2024-06-30Cons.Net sales
Revenue¥1.6bn2023-01-01 → 2023-12-31Cons.Net sales (5-year summary)
Revenue¥501m2023-01-01 → 2023-06-30Cons.Net sales
Operating income−¥1.1bn2024-01-01 → 2024-06-30Cons.Operating income
Operating income−¥864m2023-01-01 → 2023-06-30Cons.Operating income
Ordinary income−¥1.1bn2024-01-01 → 2024-06-30Cons.Ordinary income
Ordinary income−¥1.1bn2023-01-01 → 2023-12-31Cons.Ordinary income loss (5-year summary)
Ordinary income−¥868m2023-01-01 → 2023-06-30Cons.Ordinary income
Profit before tax−¥1.1bn2024-01-01 → 2024-06-30Cons.Income before income taxes
Profit before tax−¥869m2023-01-01 → 2023-06-30Cons.Income before income taxes
Net income (owners)−¥1.1bn2024-01-01 → 2024-06-30Cons.Profit loss attributable to owners of parent
Net income (owners)−¥1.2bn2023-01-01 → 2023-12-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)−¥886m2023-01-01 → 2023-06-30Cons.Profit loss attributable to owners of parent
Net income−¥1.1bn2024-01-01 → 2024-06-30Cons.Profit loss
Net income−¥886m2023-01-01 → 2023-06-30Cons.Profit loss
Total assets¥3.7bnat 2024-06-30Cons.Assets
Total assets¥4.3bnat 2023-12-31Cons.Assets
Total assets¥4.6bnat 2023-06-30Cons.Total assets (5-year summary)
Total liabilities¥470mat 2024-06-30Cons.Liabilities
Total liabilities¥472mat 2023-12-31Cons.Liabilities
Net assets / equity¥3.2bnat 2024-06-30Cons.Net assets
Net assets / equity¥3.9bnat 2023-12-31Cons.Net assets
Net assets / equity¥4.1bnat 2023-06-30Cons.Net assets (5-year summary)
Cash and deposits¥3.0bnat 2024-06-30Cons.Cash and deposits
Cash and deposits¥2.9bnat 2023-12-31Cons.Cash and deposits
Cash & equivalents¥3.0bnat 2024-06-30Cons.Cash and cash equivalents
Cash & equivalents¥2.9bnat 2023-12-31Cons.Cash and cash equivalents
Cash & equivalents¥3.7bnat 2023-06-30Cons.Cash and cash equivalents
Cash & equivalents¥3.4bnat 2022-12-31dCons.Cash and cash equivalents
Operating cash flow−¥222m2024-01-01 → 2024-06-30Cons.Net cash provided by used in operating activities
Operating cash flow−¥1.7bn2023-01-01 → 2023-12-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow−¥939m2023-01-01 → 2023-06-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥7m2024-01-01 → 2024-06-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥11m2023-01-01 → 2023-12-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥7m2023-01-01 → 2023-06-30Cons.Net cash provided by used in investment activities
Financing cash flow¥279m2024-01-01 → 2024-06-30Cons.Net cash provided by used in financing activities
Financing cash flow¥1.2bn2023-01-01 → 2023-12-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow¥1.2bn2023-01-01 → 2023-06-30Cons.Net cash provided by used in financing activities
EPS (basic)¥-63.252024-01-01 → 2024-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-68.622023-01-01 → 2023-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-53.812023-01-01 → 2023-06-30Cons.Basic earnings loss per share (5-year summary)
Equity ratio87.2%at 2024-06-30Cons.Equity to asset ratio (5-year summary)
Equity ratio89.1%at 2023-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio89.9%at 2023-06-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 8
SegmentItemPeriodValue
jpcrp040300-q2r_E00987-000Drug Discovery Businessreportable segmentsegment profit2024-01-01 → 2024-06-30−¥1.1bn
jpcrp040300-q2r_E00987-000Drug Discovery Support Businessreportable segmentrevenue2024-01-01 → 2024-06-30¥316m
jpcrp040300-q2r_E00987-000Drug Discovery Support Businessreportable segmentrevenue external2024-01-01 → 2024-06-30¥316m
jpcrp040300-q2r_E00987-000Drug Discovery Support Businessreportable segmentsegment profit2024-01-01 → 2024-06-30−¥24m
jpcrp040300-q2r_E00987-000Drug Discovery Businessreportable segmentsegment profit2023-01-01 → 2023-06-30−¥1.0bn
jpcrp040300-q2r_E00987-000Drug Discovery Support Businessreportable segmentrevenue2023-01-01 → 2023-06-30¥501m
jpcrp040300-q2r_E00987-000Drug Discovery Support Businessreportable segmentrevenue external2023-01-01 → 2023-06-30¥501m
jpcrp040300-q2r_E00987-000Drug Discovery Support Businessreportable segmentsegment profit2023-01-01 → 2023-06-30¥169m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 417
ItemContextValueUnit
Year to quarter end consolidated statement of income (text)CurrentYTDDurationText · Plus
Year to quarter end consolidated statement of comprehensive income (text)CurrentYTDDurationText · Plus
Quarterly consolidated statement of cash flows (text)CurrentYTDDurationText · Plus
Notes uncertainties of entitys ability to continue as going concern quarterly consolidated financial statements (text)CurrentYTDDurationText · Plus
Major components of selling general and administrative expenses (text)CurrentYTDDurationText · Plus
Reconciliation of ending balance of cash and cash equivalents with account balances per balance sheet (text)CurrentYTDDurationText · Plus
Notes when there is significant changes in amounts of equity (text)Prior1YTDDurationText · Plus
Notes when there is significant changes in amounts of equity (text)CurrentYTDDurationText · Plus
Notes segment information etc quarterly consolidated financial statements (text)CurrentYTDDurationText · Plus
Footnotes regarding segment information table (text)Prior1YTDDurationText · Plus
Information about impairment loss of non current assets or goodwill etc for each reportable segment (text)Prior1YTDDurationText · Plus
Footnotes regarding segment information table (text)CurrentYTDDurationText · Plus
Information about impairment loss of non current assets or goodwill etc for each reportable segment (text)CurrentYTDDurationText · Plus
Notes revenue recognition quarterly consolidated financial statements (text)CurrentYTDDurationText · Plus
Notes per share information quarterly consolidated financial statements (text)CurrentYTDDurationText · Plus
Other information consolidated financial statements etc (text)CurrentYTDDurationText · Plus
Information about company which provides guarantee to reporting company (text)FilingDateInstantText · Plus

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2023-12-31pass
balance sheet identityconsolidated 2024-06-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-12-31pass
statement vs summary · net assetsconsolidated 2024-06-30pass
statement vs summary · net income attributable to parentconsolidated 2023-01-01/2023-06-30pass
statement vs summary · net income attributable to parentconsolidated 2024-01-01/2024-06-30pass
statement vs summary · operating cash flowconsolidated 2023-01-01/2023-06-30pass
statement vs summary · operating cash flowconsolidated 2024-01-01/2024-06-30pass
statement vs summary · revenueconsolidated 2023-01-01/2023-06-30pass
statement vs summary · revenueconsolidated 2024-01-01/2024-06-30pass
statement vs summary · total assetsconsolidated 2023-12-31pass
statement vs summary · total assetsconsolidated 2024-06-30pass